AssetMark Inc
CTXR icon

AssetMark Inc’s Citius Pharmaceuticals CTXR Stock Holding History

AssetMark Inc’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225 Hold
372
– – ﹤0.01% 3412
2026
Q1 		$335 Buy
+372
New +$300 ﹤0.01% 3251

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

AssetMark Inc's CTXR Position: Q2 2026 in Review

AssetMark Inc held its Citius Pharmaceuticals (CTXR) position steady in Q2 2026 at 372 shares worth $225. The position accounts for ﹤0.01% of the portfolio, ranked #3412.

AssetMark Inc first reported a position in CTXR in Q1 2026 and has held it in 2 quarters since. The position peaked at $335 in Q1 2026. 42 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • AssetMark Inc held 372 shares of Citius Pharmaceuticals worth $225 as of Q2 2026.
  • AssetMark Inc left its Citius Pharmaceuticals share count unchanged in Q2 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3412 holding.
  • AssetMark Inc first reported a position in Citius Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • AssetMark Inc's Citius Pharmaceuticals position peaked at $335 in Q1 2026.
  • 42 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.